Insider Buys 10M ANNOVIS Shares Ahead of Low‑Price Public Offering—What It Means for Investors
Insider buys 10 M shares of ANNOVIS BIO at $1.00 ahead of a low‑price public offering, signaling confidence in a near‑term price rebound and a boost to clinical‑trial funding.
4 minutes to read